Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Vistagen Therapeutics Inc
(NQ:
VTGN
)
3.320
+0.090 (+2.79%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Jun 25, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Vistagen Therapeutics Inc
< Previous
1
2
3
4
5
6
Next >
Vistagen Announces Issuance of U.S. Patent for PH80 Nasal Spray for Treatment of Migraine
March 01, 2023
From
Vistagen
Via
Business Wire
InvestorNewsBreaks — VistaGen Therapeutics Inc. (NASDAQ: VTGN) Releases Q3 2023 Financial Results, Corporate Update
February 08, 2023
Via
Investor Brand Network
Vistagen Provides Corporate Update and Reports Fiscal 2023 Third Quarter Financial Results
February 07, 2023
From
Vistagen
Via
Business Wire
InvestorNewsBreaks – VistaGen Therapeutics Inc. (NASDAQ: VTGN) to Host Q3 Fiscal 2023 Results Call and Webcast
February 06, 2023
Via
Investor Brand Network
Vistagen to Report Fiscal Year 2023 Third Quarter Financial Results on February 7, 2023
February 06, 2023
From
Vistagen
Via
Business Wire
InvestorNewsBreaks – VistaGen Therapeutics Inc. (NASDAQ: VTGN) Announces Closing of Strategic Acquisition
February 02, 2023
Via
Investor Brand Network
Topics
Intellectual Property
Exposures
Intellectual Property
Vistagen Announces Closing of Pherin Pharmaceuticals Acquisition
February 02, 2023
From
Vistagen
Via
Business Wire
InvestorNewsBreaks — VistaGen Therapeutics Inc. (NASDAQ: VTGN) Doses First Participants in PH10 Phase 1 Clinical Trial
January 24, 2023
Via
Investor Brand Network
Exposures
Product Safety
Vistagen Announces First Participants Dosed in Phase 1 Clinical Trial of PH10, an Investigational Pherine Nasal Spray for Major Depressive Disorder
January 24, 2023
From
Vistagen
Via
Business Wire
InvestorNewsBreaks — VistaGen Therapeutics Inc. (NASDAQ: VTGN) Set to Commence Antidepressant Nasal Spray Trial This Quarter
January 19, 2023
Via
Investor Brand Network
Exposures
Product Safety
Vistagen Poised To Begin Phase 1 Trial Of A Fast-Acting Antidepressant Nasal Spray In First Quarter Of 2023
January 19, 2023
By Rachael Green, Benzinga
Via
TheNewswire.com
Exposures
Product Safety
InvestorNewsBreaks – VistaGen Therapeutics Inc. (NASDAQ: VTGN) Completes 4-Week Treatment Protocol for Final Patient in Phase 2 AjDA Trial
January 10, 2023
Via
Investor Brand Network
Vistagen Announces Completion of Last Patient, Last Visit in Phase 2 Clinical Trial of PH94B for the Treatment of Adjustment Disorder with Anxiety
January 10, 2023
From
Vistagen
Via
Business Wire
InvestorNewsBreaks — VistaGen Therapeutics Inc. (NASDAQ: VTGN) Takes Key Steps to Protect, Enhance IP Program
January 03, 2023
Via
Investor Brand Network
Topics
Intellectual Property
Exposures
Intellectual Property
Vistagen Advances Intellectual Property Program to Expand Patent Protection for PH94B to Include Treatment of Adjustment Disorder
December 30, 2022
From
Vistagen
Via
Business Wire
InvestorNewsBreaks – VistaGen Therapeutics Inc. (NASDAQ: VTGN) Announces Plans to Acquire Pherin Pharmaceuticals Inc.
December 21, 2022
Via
Investor Brand Network
Vistagen to Acquire Pherin Pharmaceuticals
December 21, 2022
From
Vistagen
Via
Business Wire
KCSA Mental Health Virtual Investor Conference: Presentations Now Available for Online Viewing
December 16, 2022
Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.com
From
Virtual Investor Conferences
Via
GlobeNewswire
KCSA Mental Health Virtual Investor Conference Agenda Announced for December 15th
December 13, 2022
Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.com
From
Virtual Investor Conferences
Via
GlobeNewswire
InvestorNewsBreaks — VistaGen Therapeutics Inc. (NASDAQ: VTGN) Announces FDA Fast Track Designation for Development of Proprietary MDD Treatment
December 06, 2022
Via
Investor Brand Network
Exposures
Product Safety
Vistagen Receives FDA Fast Track Designation for Development of PH10 to Treat Major Depressive Disorder
December 06, 2022
From
Vistagen
Via
Business Wire
Vistagen Receives FDA “Study May Proceed” Letter Under its Investigational New Drug Application for PH10 to Treat Major Depressive Disorder
November 30, 2022
From
Vistagen
Via
Business Wire
InvestorNewsBreaks — VistaGen Therapeutics Inc. (NASDAQ: VTGN) Publishes Positive Preclinical Findings Related to AV-101
November 17, 2022
Via
Investor Brand Network
Vistagen Announces Publication in Cells Demonstrating AV-101’s Potential for Treating Levodopa-Induced Dyskinesia in Patients with Parkinson's Disease
November 17, 2022
From
Vistagen
Via
Business Wire
InvestorNewsBreaks — VistaGen Therapeutics Inc. (NASDAQ: VTGN) Releases Q2 2023 Financial Report, Corporate Update
November 11, 2022
Via
Investor Brand Network
Exposures
Product Safety
Vistagen Reports Second Quarter Financial Results and Provides Corporate Update
November 10, 2022
From
Vistagen
Via
Business Wire
InvestorNewsBreaks – VistaGen Therapeutics Inc. (NASDAQ: VTGN) to Host Q2 2023 Financial Results Call, Webcast
November 04, 2022
Via
Investor Brand Network
Vistagen to Report Fiscal Year 2023 Second Quarter Financial Results on November 10, 2022
November 04, 2022
From
Vistagen
Via
Business Wire
InvestorNewsBreaks – VistaGen Therapeutics Inc. (NASDAQ: VTGN) to Participate at Stifel 2022 Healthcare Conference
November 03, 2022
Via
Investor Brand Network
Vistagen to Present at Stifel 2022 Healthcare Conference
November 03, 2022
From
Vistagen
Via
Business Wire
< Previous
1
2
3
4
5
6
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.